European Investment Bank

Orano is a France-based energy company focused on nuclear power, offering end-to-end capabilities across the nuclear fuel cycle, reactor design and construction, and operating services. It handles transportation, storage, and management of nuclear materials, packaging and transport services, dismantling of nuclear installations, specialized maintenance, and both nuclear and non-nuclear engineering. The company also pursues renewable energy initiatives through partnerships to develop high-technology solutions for low-carbon power generation, combining nuclear and renewable strengths to support safer, lower-emission energy.

Nomagic, Inc. is a technology company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce. The company develops smart pick-and-place robotic systems that enhance efficiency, flexibility, and reliability in warehouses. By automating tedious tasks, Nomagic's solutions help reduce fulfillment costs and address labor shortages, allowing operations to scale effectively and operate around the clock. Powered by artificial intelligence, their robotic systems continuously learn and adapt to changing conditions, enabling warehouse operators to improve agility and ensure reliable delivery of goods. Nomagic's technology has been implemented in notable locations, including packing lines at Cdiscount, a leading French eCommerce platform.

Median Technologies develops medical imaging software and services for oncology clinical trials and cancer care. It offers iBiopsy, an AI-powered imaging biomarker phenotyping platform that supports translational research and biomarker identification, and iSee, an image analysis and management solution for clinical trials. The company standardizes and automates the interpretation of medical images to optimize cancer diagnosis and the assessment of treatment response, and provides imaging contract research services such as study startup, image and clinical data management, scientific consulting, independent reviews, image data processing, site support, and study close-out. Median Technologies serves drug development and patient care markets with international reach and has partnerships with industry players to expand imaging capabilities. It was founded in 2002 and is headquartered in Valbonne, France.

Cellectis is a clinical-stage biotechnology company specializing in immuno-oncology. It develops allogeneic T-cell therapies using gene-editing technologies, focusing on chimeric antigen receptor (CAR) T-cells targeting various cancers.

Founded in Lyon, France in 2009 and part of the LyonBiopôle cluster, Fab’entech is a biopharmaceutical company developing and commercializing innovative passive immunotherapeutic solutions. These are based on specific polyclonal immunoglobulins [F(ab’)₂] for treating emerging infectious diseases and certain drug intoxications.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Endesa is a leading electric utility company operating primarily in Spain and Portugal since its founding in 1944. It generates electricity from diverse sources including hydroelectric, nuclear, natural gas, oil, solar, and wind, with an installed capacity of over 21 gigawatts. Endesa serves approximately 11.2 million customers and employs around 10,000 people directly.

SiPearl is a French semiconductor company specializing in designing high-performance, low-power microprocessors for exascale supercomputers. Its flagship product, Rhea, based on Arm Neoverse V1 architecture and manufactured using TSMC's N6 or better processes, aims to advance computing infrastructure for critical applications such as HPC, AI, and data centers.

Reden Solar develops, finances, builds, and operates solar photovoltaic power plants across Europe and Latin America. The company has an installed portfolio of 762 MW and a development pipeline of about 15 GW. Its core markets are France and Spain, with recent expansion into Greece and Italy. Reden Solar offers a range of photovoltaic installations, including agricultural greenhouses, ground-mounted plants, photovoltaic shelters, and rooftops, enabling clients to generate clean energy.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

AB Science, established in 2001 by a team of researchers, clinicians, and entrepreneurs, is a France-based pharmaceutical company focused on developing innovative treatments for significant unmet medical needs. The company specializes in the research, discovery, development, and marketing of protein kinase inhibitors, particularly tyrosine kinase inhibitors. These targeted therapies aim to treat various diseases, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases, with applications in both human and veterinary medicine.

Cellectis is a clinical-stage biotechnology company specializing in immuno-oncology. It develops allogeneic T-cell therapies using gene-editing technologies, focusing on chimeric antigen receptor (CAR) T-cells targeting various cancers.

AB Science, established in 2001 by a team of researchers, clinicians, and entrepreneurs, is a France-based pharmaceutical company focused on developing innovative treatments for significant unmet medical needs. The company specializes in the research, discovery, development, and marketing of protein kinase inhibitors, particularly tyrosine kinase inhibitors. These targeted therapies aim to treat various diseases, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases, with applications in both human and veterinary medicine.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

OVH APAC is a leading cloud provider known for its innovative and cost-effective solutions tailored for a diverse clientele, ranging from startups to large enterprises. Founded in 1999 by Octave Klaba and based in France, OVH offers a comprehensive portfolio of services, including web hosting, dedicated servers, cloud solutions, domain registration, and VOIP telephony. The company distinguishes itself through its proprietary global fiber-optic network and green data centers, which enable optimal performance and reliability. With a commitment to research and development and complete control over its supply chain, OVH delivers high-quality products and exceptional customer service. Additionally, OVH has established a strong partnership with VMware, integrating advanced software solutions to enhance network performance and streamline service delivery for its customers. As a result, OVH is recognized as one of the top internet hosting companies globally, serving millions of customers with cutting-edge technology and expertise.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Prophesee develops neuromorphic vision systems that mimic the human eye's functionality. Its patented sensors and AI algorithms enable unprecedented speed (>10,000 fps), dynamic range (>120dB), data volume reduction (10x to 1000x), and power efficiency (<10 mW). Prophesee serves clients in autonomous driving, mobile devices, IoT, and industry sectors. Founded in Paris in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch, and Luca Verre, the company is backed by leading international investors.

Nomagic, Inc. is a technology company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce. The company develops smart pick-and-place robotic systems that enhance efficiency, flexibility, and reliability in warehouses. By automating tedious tasks, Nomagic's solutions help reduce fulfillment costs and address labor shortages, allowing operations to scale effectively and operate around the clock. Powered by artificial intelligence, their robotic systems continuously learn and adapt to changing conditions, enabling warehouse operators to improve agility and ensure reliable delivery of goods. Nomagic's technology has been implemented in notable locations, including packing lines at Cdiscount, a leading French eCommerce platform.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Stilla Technologies is a Paris-based biotechnology company that accelerates genetic test development by delivering the Naica System, a digital PCR (dPCR) platform. Built on microfluidic innovations, the Naica System aims to broaden dPCR from a specialized tool to a widely accessible technology across life sciences, including research, therapeutics, and omics. The platform supports multiple chemistries and multiplexing to enable high-resolution genetic analysis and actionable insights across applications such as cancer and liquid biopsy, cell and gene therapies, infectious disease detection, and food and environmental testing. Founded in 2013 and headquartered in Villejuif, France, the company serves customers globally and focuses on simplifying image analysis and data exploration to help researchers derive clear results from complex genomic data.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Bouygues Telecom is a prominent telecommunications operator in France, offering a wide range of services that include mobile, fixed-line, television, internet, and cloud computing. The company serves approximately 11.1 million mobile customers and 2.1 million fixed broadband customers, including over 1.5 million professional and corporate clients. Renowned for its innovative approach, Bouygues Telecom has introduced several pioneering products, such as the first unlimited call plans, fixed-mobile convergence offers for corporate customers, and the quadruple play solution known as ideo. The company also launched B&YOU, a web-only offer that revolutionized mobile telephony. With a mobile network that covers 99% of the population and a rapidly expanding 4G network, Bouygues Telecom is committed to enhancing customer experience through its dedicated team of over 9,000 employees and a robust customer service framework that includes 2,000 advisers and 2,500 sales staff. The company's focus on innovation and customer satisfaction positions it as a key player in the French telecommunications market.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

Median Technologies develops medical imaging software and services for oncology clinical trials and cancer care. It offers iBiopsy, an AI-powered imaging biomarker phenotyping platform that supports translational research and biomarker identification, and iSee, an image analysis and management solution for clinical trials. The company standardizes and automates the interpretation of medical images to optimize cancer diagnosis and the assessment of treatment response, and provides imaging contract research services such as study startup, image and clinical data management, scientific consulting, independent reviews, image data processing, site support, and study close-out. Median Technologies serves drug development and patient care markets with international reach and has partnerships with industry players to expand imaging capabilities. It was founded in 2002 and is headquartered in Valbonne, France.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

Prophesee develops neuromorphic vision systems that mimic the human eye's functionality. Its patented sensors and AI algorithms enable unprecedented speed (>10,000 fps), dynamic range (>120dB), data volume reduction (10x to 1000x), and power efficiency (<10 mW). Prophesee serves clients in autonomous driving, mobile devices, IoT, and industry sectors. Founded in Paris in 2014 by Ryad Benosman, Bernard Gilly, Christoph Posch, and Luca Verre, the company is backed by leading international investors.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

MotorK is a SaaS provider specializing in digital sales and marketing solutions for the automotive retail industry across EMEA. With over 400 employees and offices in eight countries, MotorK empowers car manufacturers and dealers to enhance customer experience through integrated digital products and services.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Navya SA is a prominent French company specializing in autonomous vehicle technology and smart shared mobility solutions. Founded in 2014 and headquartered in Villeurbanne, France, Navya develops, manufactures, and services a range of driverless electric vehicles, including autonomous shuttles and cabs. The company primarily caters to municipalities, industrial sites, universities, theme parks, and airports, and its products are available in the United States, EMEA, and Asia-Pacific regions. Navya has been a pioneer in the autonomous mobility sector, launching its first shuttle, the AUTONOM®SHUTTLE, in 2015, with over 100 units produced and sold in multiple countries. The AUTONOM®CAB, introduced in 2017, is set to undergo road tests soon. With a workforce of more than 200 employees in France and the United States, Navya combines advanced robotic and digital technologies to deliver innovative mobility solutions.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

October is a pan-European lending platform that aims to empower businesses by simplifying access to funding. Founded in France in 2014 under the name Lendix, the company emerged following regulatory changes that disrupted traditional banking practices. With offices in France, Spain, Italy, and the Netherlands, October operates an online marketplace that connects private investors with enterprises of various sizes. This platform allows investors to finance businesses directly, offering fully disclosed terms and facilitating a streamlined investment process. Institutional lenders complement individual contributions, ensuring borrowers benefit from high success rates and quick processing times. October's mission is to democratize finance, providing a secure and efficient way for individuals to invest in the real economy.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Forsee Power SAS, founded in 2007 and based in Ivry-sur-Seine, France, specializes in the design and manufacture of smart lithium-ion battery systems. The company serves various sectors, including electric transportation, portable and mobile equipment, and energy storage. Its product offerings include modular battery systems for electric and hybrid vehicles, trams, electric trains, buses, trucks, and marine applications such as ships and ferries. Additionally, Forsee Power provides power systems for mobile and connected devices across numerous fields, including medical equipment, electric scooters, and robotics. The company's focus on innovation and customer satisfaction aims to facilitate a sustainable energy transition and enhance the performance of smart mobility and life devices globally.

SunPartner Technologies, founded in 2008 and based in Rousset, France, specializes in the development and commercialization of advanced photovoltaic technologies. The company focuses on integrating solar solutions into various applications, including mobile devices and infrastructure. Its notable products include Wysips Crystal, an ultra-thin and transparent photovoltaic material designed for smartphones and smartwatches, and Wysips Graphics, which incorporates solar cells into connected devices. Additionally, SunPartner offers Wysips Reflect for reflective screens and Wysips Cameleon for signage and billboards. The company also explores innovations in communication technologies, such as Light-Fidelity, which utilizes visible light for data transmission, applicable in smart cities and location-based services. Through its diverse portfolio, SunPartner aims to enhance energy autonomy and promote sustainable energy solutions in multiple sectors.

Electro Power Systems operates in the sustainable energy sector, focusing on hybrid-storage solutions and microgrids that convert intermittent renewable energy into a reliable power source. Headquartered in Paris, with research, development, and manufacturing facilities in Italy, the company has developed innovative hybrid energy storage technologies, supported by 125 patents and over a decade of research and development. These solutions are designed to stabilize electrical grids with high levels of renewable energy integration in developed countries and provide cost-effective off-grid power in emerging economies without relying on subsidies. Electro Power Systems has successfully implemented and is commissioning 36 large-scale projects, including off-grid hybrid systems and grid support systems, totaling over 47 MWh of capacity across 21 countries, serving more than 165,000 customers daily.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Bordeaux Métropole Énergies (BME) is a semi-public energy group headquartered in Bordeaux, France, and is 76% controlled by Bordeaux Métropole. BME is an important actor in the local energy transformation, servicing the Gironde region and the surrounding Bordeaux metropolitan area.